Open-label, single arm, phase II study for evaluation of complete response rate at surgery after NEOadjuvant treatment with SUnitinib and docetaxel in patients with newly diagnosed large operable or locally advanced breast cancer.

Trial Profile

Open-label, single arm, phase II study for evaluation of complete response rate at surgery after NEOadjuvant treatment with SUnitinib and docetaxel in patients with newly diagnosed large operable or locally advanced breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2011

At a glance

  • Drugs Docetaxel (Primary) ; Sunitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOSU
  • Most Recent Events

    • 17 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top